Special Issue "Molecular Pathology of Lung Cancer"

A special issue of Journal of Molecular Pathology (ISSN 2673-5261).

Deadline for manuscript submissions: 15 December 2021.

Special Issue Editor

Dr. Hans Brunnström
E-Mail Website
Guest Editor
Department of Pathology, Lund University, Lund, Sweden
Interests: pathology; cancer; lung cancer; immunohistochemistry; classification; molecular profiling

Special Issue Information

Dear Colleagues, 

We have seen a rapid advancement in molecular technologies and use of such methods in the daily practice of lung cancer pathology. Today, there are numerous approvals and ongoing trials for treatments linked to predictive molecular alterations or biomarkers in lung cancer.

For lung cancer investigations, the small size of typical samples (biopsies, cytology, and liquid-based samples) presents a major challenge to comprehensive molecular analysis. In addition to tumor material requirements and coverage, time and cost are also issues that may affect the choice of molecular methods in clinical practice.

Given the advances and increased knowledge in molecular pathology and tumor biology, molecular profiling in the future may contribute even more to subtyping/classification of tumors, distinguishing lung cancers from pulmonary metastases or benign/non-neoplastic lesions, and separation of synchronous lung cancers from intrapulmonary metastases, among others. Likewise, the role of molecular pathology in early detection, tumor heterogeneity, and progression and resistance mechanisms will likely expand.

We invite investigators to contribute original research articles as well as review articles and short communications. Potential topics include, but are not limited to, the following:

  • discovery and/or validation of diagnostic or treatment-predictive molecular biomarkers;
  • multiplex molecular techniques for histology, cytology, and liquid-based samples;
  • molecular testing and strategies that improve turnaround time and cost;
  • molecular pathology for understanding tumor subtyping/classification, progression, and heterogeneity.

Dr. Hans Brunnström
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Molecular Pathology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnostic method
  • liquid biopsy
  • lung cancer
  • molecular analysis
  • precision medicine
  • predictive biomarker

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Case Report
Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report
J. Mol. Pathol. 2020, 1(1), 36-42; https://doi.org/10.3390/jmp1010006 - 03 Nov 2020
Viewed by 858
Abstract
In July 2020, an active smoker, 63-year old man was admitted to the oncology unit of A.O.R.N. Sant’Anna e San Sebastiano (Caserta, Italy). Chest radiology highlighted right pleural effusion. Total-body CT scanning revealed a solid lesion with lobulated contours in the apical segment [...] Read more.
In July 2020, an active smoker, 63-year old man was admitted to the oncology unit of A.O.R.N. Sant’Anna e San Sebastiano (Caserta, Italy). Chest radiology highlighted right pleural effusion. Total-body CT scanning revealed a solid lesion with lobulated contours in the apical segment of the upper right lobe. The patient’s oncologist requested a molecular assessment of EGFR, ALK, ROS1, BRAF, and KRAS, as well as an evaluation of PD-L1 expression level. To this end, we carried out NGS analysis, on DNA extracted from cytospins, by adopting a custom-designed NGS panel (SiRe®). Overall, no actionable mutations in the tested genes were identified. Conversely, concomitant BRAF exon 11 p.G469A and a KRAS exon 4 p.A146T mutations were detected. Owing to the limited data on the presence of KRAS exon 4 p.A146T point mutation in lung adenocarcinoma patients, a further molecular confirmatory analysis was carried out with a dedicated KRAS cartridge on a fully automated real time polymerase chain reaction. When DNA was extracted from the TTF-1 positive tumor cell slide, the same KRAS alteration was observed. Unfortunately, the patient died in August 2020 before having the chance to start any type of treatment. Full article
(This article belongs to the Special Issue Molecular Pathology of Lung Cancer)
Show Figures

Figure 1

Back to TopTop